FDA.
Company
- Reports this week
- 2
- Active events
- 12
- Connections
- 3,221
What's happening
Active this week
-
Indian products were subject to an FDA recall.Some support5 reports1 development inside
-
FDA and HHS jointly presented food safety reforms, reviewing ultraprocessed food definitions and calling for congressional action on the GRAS program.Well supported3 reports1 development inside
-
FDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.Some support2 reports
-
The administration has signed an executive order and issued priority vouchers to accelerate the drug approval process through the FDA.Well supported4 reports2 developments inside
-
An HHS official commented on an FDA program, following Marty Makary's departure from the agency.Some support1 report
-
Alps Group Inc launched a PCI lab in Kuala Lumpur and aims to be a reference platform in Southeast Asia, while FDA and EMA issue new testing guidelines.Some support1 report
-
Kyverna Therapeutics announced its trial design is FDA-aligned and hosted a virtual KOL event.Some support2 reports1 development inside
-
Forbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.Some support1 report
-
CorMedix and Mundipharma are collaborating on a product pipeline for REZZAYO filing, with pricing tied to post-TDAPA reimbursement.Well supported4 reports
-
FDA approval coincided with Donald Trump's press conference on November 11, 2026.Some support1 report
-
Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.Some support2 reports
-
DBV Technologies is seeking regulatory acceptance for its product from the FDA.Some support1 report
Earlier this month
-
FDA approved combination clearances for Elanco's Experior use on June 27, 2025.Some support4 reports
-
FDA expanded approval for teplizumab treatment on November 11, 2026.Some support1 report
-
The FDA is involved in regulating drug approvals for GLP-1 Receptor Agonists.Some support2 reports
-
FDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.Some support1 report
-
An industrial event related to a manufacturing crisis is triggering regulatory clocks overseen by the FDA.Some support1 report
-
Chris Carr, Georgia Attorney General, seeks stricter state laws following FDA warnings about kratom.Well supported5 reports
-
A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.Some support2 reports1 development inside
-
FDA approved a drug based on UVA research led by Xuemei Huang.Some support3 reports
-
FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.Some support6 reports
-
CalciMedica reported trial results from La Jolla and is seeking FDA alignment on its trials.Some support1 report
-
The LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc., is currently undergoing FDA review for clearance, with its patent expanding potential applications.Well supported4 reports
-
The FDA has issued a warning regarding a company due to quality lapses and is facing investigation over securities law violations.Some support3 reports1 development inside
-
BFA is investigating potential securities violations while the FDA issues a product safety warning to Once Upon a Farm, PBC.Some support1 report
-
FDA reached agreement on NDA submission plan regarding Ocular Therapeutix.Well supported6 reports
-
Funding lead clinical programs for severe refractory c in the US through potential FDA approval.Some support1 report
-
HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.Well supported19 reports1 development inside
-
The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.Well supported6 reports3 developments inside
-
The FDA's authorization decision sparked criticism from the American Lung Association, which was also involved in a public statement via Thomas Carr.Some support1 report
-
A company with FDA-approved therapies used LinkedIn for information and its board approved a stock award for CFO hiring.Some support1 report
-
The FDA approved Miplyffa for the treatment of Niemann-Pick disease.Some support2 reports
-
iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.Some support2 reports
-
UK and US regulatory bodies are setting submission targets and offering R&D rebate programs to companies.Some support1 report
-
The FDA suspended licenses of outlets linked to Zepto and Domino's following a statewide order in Maharashtra.Well supported17 reports2 developments inside
-
An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.Some support1 report1 development inside
-
Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.Well supported5 reports
-
Kura Oncology announced the commercialization of an FDA-approved drug and began using LinkedIn for company information.Some support1 report
-
Mesoblast received FDA approval for a specific product on June 1st, led by CEO Silviu Itescu.Some support2 reports
-
The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.Well supported6 reports
-
FDA failed to update warning labels despite confirmed risks associated with a product.Some support1 report
-
FDA launches food safety campaigns and crackdowns in Maharashtra and Karnataka.Well supported3 reports2 developments inside
-
FDA granted Fast Track designation to SAB-142 on November 1, 2026.Some support2 reports
-
The FDA provided funding for the new vessel M/V Captain Dinsmore in May 2026.Some support1 report
-
Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.Some support1 report
-
Legislation requires the FDA to study formula metals, while Donald Trump endorses a candidate focused on economic growth.Some support1 report
-
FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.Some support3 reports
-
FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.Some support3 reports
-
Pixee Medical appointed Kristoff Goson as its new CEO on June 29, 2026, while also receiving 510(k) clearance from the FDA for its platform, which is used in over 20 countries.Some support4 reports
-
Precigen's therapy was approved by the FDA and listed on Nasdaq, while Trump-era tariffs are reported to benefit certain AI stocks.Well supported3 reports
-
FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.Some support1 report
-
Discussion on the limits of pharmacotherapy and the role of FDA approvals.Some support1 report
-
Eton secures exclusive U.S. commercialization rights, with FDA acceptance driving the Anaphylm PDUFA date.Some support1 report
-
Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.Some support1 report2 developments inside
-
Hemogenyx Pharmaceuticals Plc submitted an IND application for its HG-CT-1 therapy with the FDA and is building infrastructure for early commercialization in Europe.Well supported6 reports
-
FDA approved ZUSDURI, an innovative formulation of mitomycin, for bladder cancer.Some support2 reports
-
The FDA granted Fast Track Designation for RAD101, following company announcements made on July 29, 2025, from Sydney.Some support2 reports
-
Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.Well supported11 reports1 development inside
-
AtriCure, Inc. reported revenue via NASDAQ and received FDA 510(k) clearance for its device.Some support1 report
-
The FDA cited Once Upon a Farm, PBC for product risk causing airway obstruction.Some support2 reports
No events began in the chosen period. Widen it, or reset.
What's reaching FDA
Events traced to FDA, step by step, newest first- New powder-based mRNA vaccine research may change FDA review standardsNew powder-based mRNA vaccine research may change FDA review standardsPossible
- Florida's transition may shift state regulatory challenges with FDAFlorida's transition may shift state regulatory challenges with FDAPossible
- Domestic production push may require FDA to adjust drug standardsThe FDA may need to adjust regulatory requirements for domestic pharmaceutical inputsPossible
- Alcon's new cell therapy requires FDA regulatory reviewThe FDA must review the specialized cell therapy acquired by Alcon.Possible
- How could Beam Therapeutics' positive clinical trial results affect the FDA?Strong clinical data bolsters the case for risto-cel's BLA submissionLikely
- UAE's conditional approval of Ultomiris may influence FDA reviewUAE's conditional approval of Ultomiris may influence FDA reviewPossible
See all 46 explainers
- New clinical data may advance FDA review of CRISPR's gene therapyPositive clinical data may advance FDA review of CRISPR's gene therapyLikely
- AbbVie-IGI partnership advances drug requiring FDA reviewNew trispecific drug development may increase FDA's review workloadPossible
- DEA scheduling of SR-17018 complicates FDA's path for new pain drugsDEA scheduling of SR-17018 complicates FDA's path for new pain drugsPossible
- AGC Biologics expansion could increase FDA regulatory workloadFDA may face increased review demands from AGC Biologics' global expansionPossible
- Trump's vaccine order may force FDA to review safety standardsTrump's vaccine order may force FDA to review safety standardsPossible
- State-backed immunology research may change FDA review dynamicsState-backed immunology research may change FDA review dynamicsPossible
- Plastics health risks could influence FDA regulatory policiesPlastics health concerns may increase political pressure on the FDA's regulatory policiesPossible
- Lilly's new psychedelic drug requires FDA regulatory reviewFDA may need to adapt pathways for novel psychedelic drug candidatesPossible
- New robotic system integration may require FDA reviewThe FDA may need to review the combined robotic electrophysiology system.Possible
- FDA may need to adjust guidance amid THC product regulatory uncertaintyFDA may need to adjust guidance amid THC product regulatory uncertaintyPossible
- Sanofi's new vaccine development requires FDA regulatory oversightSanofi's new vaccine development requires FDA regulatory oversightPossible
- Vaccine deal talks in Brussels may prompt FDA regulatory reviewPolitical discussions over vaccine deals may prompt the FDA to review regulatory standards.Possible
- Legislative pressure may change FDA pathways for new antibioticsLegislative pressure may change FDA pathways for new antibioticsPossible
- New cancer treatment collaboration increases regulatory pipeline for FDAThe collaboration on new cancer therapies could increase the FDA's regulatory review pipeline.Possible
- FDA focus shifts to Catalyst Pharmaceuticals for AGAMREEFDA regulatory focus shifts to Catalyst Pharmaceuticals for AGAMREE in North AmericaLikely
- FDA may accelerate review of new mRNA cancer vaccineThe FDA may accelerate review of new mRNA cancer vaccine after landmark trial successLikely
- AbbVie's acquisition may increase FDA drug application volumeAbbVie's pipeline expansion could increase the volume of drug applications reviewed by the FDA.Possible
- Akeso's US trial expansion brings ivonescimab under FDA reviewUS clinical trial expansion increases FDA oversight of ivonescimab.Likely
- Labcorp's new prenatal testing services may require FDA oversightLabcorp's expanded prenatal testing portfolio may require FDA reviewPossible
- Blocked NIH grants could slow FDA's regulatory reviewBlocked NIH research grants may slow FDA regulatory reviewPossible
- OCS's positive trial data may influence FDA review of PrivosegtorOCS's positive trial data may influence FDA review of PrivosegtorPossible
- Senate race could influence FDA regulations and healthcare policyA change in the Senate seat could influence FDA regulations and healthcare policyPossible
- FDA may coordinate with NIH on new women's health researchFDA may face increased regulatory coordination due to NIH's new research focusPossible
- Licaminlimab trial data could influence FDA's regulatory pathPositive clinical trial data could accelerate FDA review of Licaminlimab.Possible
- Marijuana rescheduling may alter FDA's drug approval oversightMarijuana rescheduling could change the regulatory framework overseen by the FDA.Possible
- FDA may review new Moderna-Merck combination drugFDA must evaluate new Moderna-Merck combination drug for melanoma treatmentPossible
- New GLP-1 research could prompt FDA review of drug pathwaysNew findings on GLP-1 drugs may prompt FDA regulatory reviewPossible
- How could the CDPH's shellfish closure affect the FDA's regulatory review process?Local shellfish contamination may inform federal food safety review processPossible
- FDA may face increased review after Guidant acquisitionFDA may face increased regulatory review following Guidant's acquisitionPossible
- Aro Biotherapeutics' data could influence FDA review of T1D drugPositive preclinical data may increase the FDA's interest in Centyrin-IFIH1 siRNA.Possible
- Funding cuts could strain FDA's ability to oversee treatmentsWeakening medical research infrastructure may compromise FDA's regulatory oversightPossible
- Embryo research ban may limit FDA's future product pipelineFDA's regulatory pipeline could be limited by restrictions on embryo researchPossible
- Liquidia settlement requires FDA to update Yutrepia's approved labelThe FDA must update Yutrepia's approved label following Liquidia's settlementLikely
- FDA may face increased demand from advanced biologic pipelineFDA may face increased demand to review complex, AI-driven biologic submissionsPossible
- Moderna/Merck cancer vaccine success increases FDA review workloadFDA faces increased regulatory demand from advanced cancer vaccine trialsPossible
- Zenas's positive clinical data may influence FDA review of obexelimabThe positive clinical data from Zenas could strengthen the FDA's review of obexelimab.Possible
- Doge's cuts may reshape FDA staffing and policyDoge's cuts may reshape FDA staffing and policyLikely
- Arvinas' positive Phase 1 data may strengthen FDA review of LRRK2 drugArvinas' positive Phase 1 data may strengthen FDA review of LRRK2 drug.Possible
- Moderna's cancer vaccine result boosts FDA approval chancesLandmark cancer vaccine study increases probability of FDA approval for Moderna/Merck therapyLikely
- AI-driven drug discovery may force FDA to adapt regulatory frameworksAI-driven drug discovery may force FDA to adapt regulatory frameworksPossible
Explainers that pass through FDA
FDA is a step on the way to someone else- Drug development for chronic cough increases CDER's review focusCDER's review workload increases as drug seeks approval for new chronic cough indicationsPossible
- Walmart must remove six lots of recalled frozen berriesWalmart must remove six lots of recalled frozen berries from shelvesReported
- Mumbai Food Establishments Face License Suspension Due to FDA DriveFDA suspends and cancels licenses of multiple food establishments in MumbaiReported
- Apple leverages FDA clearance for health features in Apple WatchApple secures FDA clearance for ECG and atrial fibrillation featuresIncludes Brind's reasoning
- How does FDA and EMA sharing global regulatory leadership affect company?FDA and EMA collaboration supports OS Therapies' global market access strategyReported
Around FDA this week
News at the entities that move FDA most-
United States of America StructuralIsraeli political figures and Hezbollah discuss ceasefire terms and troop withdrawal in Lebanon amidst heightened tensions.Moves FDA
-
Department of Health & Human Services StructuralHHS aides pressured Makary regarding vapes, while political figures debated policy stalling within the health sector.Moves FDA
-
Louisiana OperationalA crash occurred in New Orleans, located in Mississippi, on November 13, 2026.Moves FDA
-
Congress StructuralTrump eased sanctions on Russian diesel while the White House sought a peace deal with Putin, amid Congressional debate on Russia policy.Moves FDA
-
Maharashtra StructuralFadnavis supported and Patil directed fee waivers for students in drought-hit areas of Maharashtra.Moves FDA
Connections
The 40 strongest of 3,221, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Center for Devices and Radiological Health Structural
CDRH functions as a formal division of the FDA, issuing alerts and holding meetings under its designation.
-
United States of America Structural
The FDA is a regulatory agency whose existence, authority, and operational scope are formally derived from the United States government.
-
Maharashtra Structural
FDA operates as the mandated regulatory body enforcing food and drug safety standards within the jurisdiction of Maharashtra.
-
Department of Health & Human Services Structural
FDA functions as a specialized agency operating under the administrative oversight and policy mandate of the Department of Health & Human Services.
-
Drug Enforcement Administration Operational
The FDA and DEA maintain a formal regulatory partnership, jointly overseeing substance scheduling, clinical trials, and market safety.
-
Eli Lilly and Company Structural
The FDA formally regulates Eli Lilly's drug development, approval, and market activities, determining product viability and market access.
-
Kennedy Structural
Kennedy, in his leadership role, exercises direct policy oversight and structural control over the FDA's operations and regulatory agenda.
-
European Medicines Agency Operational
The FDA and EMA actively coordinate on drug approval processes, sharing regulatory guidance and evaluating submissions globally.
Show all 40 connections
-
Heidi Overton Structural
Heidi Overton is appointed to the formal leadership role of the FDA Commissioner.
-
Florida Operational
FDA and Florida engage in a dynamic regulatory relationship, characterized by federal standards setting and state legislative and litigation challenges.
-
Tukaram Mundhe Structural
Tukaram Mundhe holds the formal position of Commissioner, directing the regulatory and enforcement operations of the FDA Maharashtra.
-
Louisiana Operational
Louisiana actively challenges federal drug policies and regulations enforced by the FDA through ongoing litigation.
-
Congress Structural
The FDA's regulatory scope, funding, and operational mandates are established and controlled by legislation and oversight from Congress.
-
Center for Biologics Evaluation and Research Structural
CBER operates as a specialized research center and division under the authority of the FDA.
-
Center for Drug Evaluation and Research Structural
The Center for Drug Evaluation and Research is a formal division overseen by the FDA agency.
-
Merck Structural
FDA mandates regulatory oversight and grants market approval for Merck's pharmaceutical products.
-
Pfizer Structural
FDA formally regulates Pfizer's pharmaceutical products, controlling market entry, approvals, and license compliance.
-
Natera Structural
Natera relies on the FDA for market access, which evaluates and grants approval for its products as a companion diagnostic.
-
AstraZeneca Structural
FDA formally regulates AstraZeneca's drug development, requiring designations, approvals, and reviews for market access.
-
company Structural
The company's commercial viability and operational scope are formally dependent on the review, clearance, and approval granted by the FDA.
-
WuXi Biologics Structural
FDA formally inspects and regulates WuXi Biologics' manufacturing facilities to ensure compliance.
-
Boston Scientific Structural
The FDA regulates Boston Scientific through market approvals, safety monitoring, and required alerts.
-
Teva Pharmaceutical Industries Ltd. Structural
The FDA exercises formal regulatory authority over Teva's pharmaceutical products, governing approvals, designations, and market access.
-
Neuralink Structural
Neuralink's commercialization and device status are formally dependent on regulatory approval from the FDA.
-
Centers for Disease Control and Prevention Structural
The CDC and FDA maintain a structural partnership, coordinating outbreak responses and relying on FDA approval for vaccine recommendations.
-
Atrium Structural
Atrium received Investigational New Drug (IND) clearance from the FDA for ATR 1072.
-
Rocket Structural
The FDA formally regulates Rocket's drug development, issuing clearances, designations, and clinical holds.
-
Merck KGaA Operational
The FDA evaluates and approves pharmaceutical products submitted by Merck KGaA, granting market access based on rigorous review processes.
-
Jazz Pharmaceuticals Structural
Jazz Pharmaceuticals relies on the FDA for regulatory approval, which is required for market introduction and sales of its therapies.
-
Philip Morris International Structural
The FDA formally regulates and authorizes the marketing and products of Philip Morris International.
-
Hoffmann-La Roche Structural
FDA formally regulates Hoffmann-La Roche's pharmaceutical products, granting approvals and tracking safety for market access.
-
Intuitive Surgical Structural
The FDA functions as the mandatory regulatory gatekeeper, granting market access and operational legitimacy to Intuitive Surgical's medical devices.
-
Office of Management and Budget Structural
The Office of Management and Budget formally reviews and oversees the rulemaking and approval processes of the FDA.
-
Penumbra Structural
The FDA formally regulates Penumbra, requiring product clearances and imposing oversight models for market access.
-
Abbott Laboratories Structural
The FDA regulates Abbott Laboratories, granting product approvals, setting operational standards, and conducting oversight.
-
Vinay Prasad Structural
Vinay Prasad holds a high-ranking leadership role within the FDA, specifically overseeing the critical CBER division and gene therapy review processes.
-
Mundhe Structural
Mundhe holds the formal position of FDA Commissioner, defining the agency's operational and policy stance.
-
Medicare Operational
FDA clearance enables Medicare coverage, but Medicare actively controls access, pricing, and reimbursement for approved products.
-
Michael Davis Structural
Michael Davis was appointed to lead a key drug evaluation center within the FDA.
-
Masimo Structural
The FDA acts as the regulatory gatekeeper, granting necessary clearances for Masimo's patient monitoring technologies to enter the market.
History
Events by the month they beganNovember 2026
25 events- An HHS official commented on an FDA program, following Marty Makary's departure from the agency.
- Alps Group Inc launched a PCI lab in Kuala Lumpur and aims to be a reference platform in Southeast Asia, while FDA and EMA issue new testing guidelines.
- Forbes reported on recent drug filings submitted to the FDA and the European Medicines Agency.
- FDA approval coincided with Donald Trump's press conference on November 11, 2026.
- DBV Technologies is seeking regulatory acceptance for its product from the FDA.
- FDA expanded approval for teplizumab treatment on November 11, 2026.
- FDA accepted Axion BioSystems' Letter of Intent (LOI) for a neural assay on November 10, 2026.
- An industrial event related to a manufacturing crisis is triggering regulatory clocks overseen by the FDA.
- CalciMedica reported trial results from La Jolla and is seeking FDA alignment on its trials.
- BFA is investigating potential securities violations while the FDA issues a product safety warning to Once Upon a Farm, PBC.
- Funding lead clinical programs for severe refractory c in the US through potential FDA approval.
- The FDA's authorization decision sparked criticism from the American Lung Association, which was also involved in a public statement via Thomas Carr.
- A company with FDA-approved therapies used LinkedIn for information and its board approved a stock award for CFO hiring.
- UK and US regulatory bodies are setting submission targets and offering R&D rebate programs to companies.
- Kura Oncology announced the commercialization of an FDA-approved drug and began using LinkedIn for company information.
- FDA failed to update warning labels despite confirmed risks associated with a product.
- FDA granted Fast Track designation to SAB-142 on November 1, 2026.
- The FDA provided funding for the new vessel M/V Captain Dinsmore in May 2026.
- Cloudbreak Pharma Inc. intends to meet with the FDA to review its study findings.
- Legislation requires the FDA to study formula metals, while Donald Trump endorses a candidate focused on economic growth.
- FDA granted approvals for RASONQUE and WELTRUZA on November 4, 2026.
- Discussion on the limits of pharmacotherapy and the role of FDA approvals.
- Eton secures exclusive U.S. commercialization rights, with FDA acceptance driving the Anaphylm PDUFA date.
- AtriCure, Inc. reported revenue via NASDAQ and received FDA 510(k) clearance for its device.
- The FDA cited Once Upon a Farm, PBC for product risk causing airway obstruction.
October 2026
6 events- Indian products were subject to an FDA recall.
- FDA issued a warning letter to NeoGen regarding a product quality defect on October 7, 2026.
- Chris Carr, Georgia Attorney General, seeks stricter state laws following FDA warnings about kratom.
- FDA approved a drug based on UVA research led by Xuemei Huang.
- HHS policy allows peptides in compounding pharmacies despite FDA lack of approval, with RFK Jr. arguing for safer compounds.
- FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.
September 2026
2 eventsShow 2 earlier months
August 2026
6 events- FDA and HHS jointly presented food safety reforms, reviewing ultraprocessed food definitions and calling for congressional action on the GRAS program.
- CorMedix and Mundipharma are collaborating on a product pipeline for REZZAYO filing, with pricing tied to post-TDAPA reimbursement.
- Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
- The FDA suspended licenses of outlets linked to Zepto and Domino's following a statewide order in Maharashtra.
- FDA launches food safety campaigns and crackdowns in Maharashtra and Karnataka.
- Medicare eligibility rules affect AbbVie drug pricing, while the FDA regulates Creon's classification and approval for Medicare beneficiaries.
June 2026
21 events- The administration has signed an executive order and issued priority vouchers to accelerate the drug approval process through the FDA.
- Kyverna Therapeutics announced its trial design is FDA-aligned and hosted a virtual KOL event.
- FDA approved combination clearances for Elanco's Experior use on June 27, 2025.
- A collaboration between Bristol-Myers Squibb and Exelixis is seeking FDA clearance for an IND application regarding combination therapies.
- FDA oversees drug trials in the US and Israel for Clearmind Medicine Inc., which is listed on Nasdaq.
- The LIBERTY Endovascular Robotic System, developed by Microbot Medical Inc., is currently undergoing FDA review for clearance, with its patent expanding potential applications.
- The FDA has issued a warning regarding a company due to quality lapses and is facing investigation over securities law violations.
- FDA reached agreement on NDA submission plan regarding Ocular Therapeutix.
- The FDA is evaluating GRAIL's Galleri test as a breakthrough device, with Medicare coverage depending on the thorough FDA vetting.
- The FDA approved Miplyffa for the treatment of Niemann-Pick disease.
- iRhythm Technologies launched its Zio ECG system in Japan following FDA clearance, amid reports that Trump-era tariffs benefit AI stocks.
- An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.
- Johnson & Johnson acquired Intra-Cellular Therapies and is seeking FDA approval for related drugs.
- Mesoblast received FDA approval for a specific product on June 1st, led by CEO Silviu Itescu.
- The FDA approved Tonix Pharmaceuticals' drug, Tonmya, for use in treating fibromyalgia.
- FDA reviewed an NDA and entered a clinical study agreement for a babesiosis trial involving 60 Degrees Pharmaceuticals.
- Pixee Medical appointed Kristoff Goson as its new CEO on June 29, 2026, while also receiving 510(k) clearance from the FDA for its platform, which is used in over 20 countries.
- Precigen's therapy was approved by the FDA and listed on Nasdaq, while Trump-era tariffs are reported to benefit certain AI stocks.
- FDA approved ZUSDURI, an innovative formulation of mitomycin, for bladder cancer.
- The FDA granted Fast Track Designation for RAD101, following company announcements made on July 29, 2025, from Sydney.
- Tarsus Pharmaceuticals is seeking FDA approval in the US and is listed on the Nasdaq stock exchange.